Survey of chemotherapy‑induced nausea and vomiting in patients with urothelial carcinoma

• DOI: 10.3892/mco.2021.2384
• Publication Date: 2021-08-25T11:08:19Z
• Authors: Akira Yoshimi; Yuna Shiroma; Miku Iwata; Mariko Nakamura; Aya Torii‑Goto; Hirotake Hida; Noriko Tanaka; Masayuki Miyazaki; Kiyofumi Yamada; Yukihiro Noda
• Keywords: Carboplatin

Chemotherapy‑induced nausea and vomiting (CINV) can cause anorexia, weight loss deterioration of patient quality life. It is one the most unpleasant adverse effects chemotherapy treatment regimens. For optimal gastrointestinal symptoms during urothelial carcinoma chemotherapy, present study investigated association between therapeutic gemcitabine plus platinum [cisplatin (GC) or carboplatin (GCa)] therapies. The incidence frequency nausea/vomiting with GC split therapy (gemcitabine, 1,000 mg/m² on days 1 8; split‑dose cisplatin, 35 21‑day schedule) GCa [gemcitabine, 750‑1,000 1, 8 15; carboplatin, area under blood concentration‑time curve=5 mg min/ml (Calvert formula) day 2; 28‑day schedule] were lower compared those single‑dose cisplatin 70 schedule). However, no differences in outcomes observed among therapy, regardless renal function, demonstrated significant increases alleviating associated cancer patients carcinoma. Overall, these results suggested that administration use instead may be useful who experience CINV without compromising effectiveness.